Facing the increasingly serious problem of societal aging, the Gakken Group of Japan and Kyoto University established a new company, 'Gerok,' in August 2025 to quickly transform advanced anti-aging research results into social value.

Research Background: Based on the authoritative research by Professor Yoichi Nabeshima of Kyoto University in the field of aging, we focus on developing solutions for age-related diseases such as dementia.

Core Focus: The drug development work revolves around the anti-aging gene 'α-Klotho,' concentrating on the development and activation of small molecule compounds that can enhance its function.

Future Plan: Gerok aims to reinvest the profits from healthcare operations into research and development, creating a positive cycle, and around 2030, to apply comprehensive R&D projects covering everything from prevention to treatment to society, thereby creating new value in the global health and longevity market.